Elevation Oncology
Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. They leverage their ADC expertise to advance targeted therapies, including their pipeline of novel agents such as EO-1022, a HER3 antibody-drug conjugate. The company is committed to scientific excellence and aims to provide safer and more effective treatment options for cancer patients.
Industries
Nr. of Employees
small (1-50)
Elevation Oncology
New York, New York, United States, North America
Products
HER3-targeting antibody-drug conjugate (preclinical)
A HER3-targeting antibody-drug conjugate in preclinical development that uses site-specific glycan conjugation to attach a potent cytotoxic payload with a defined DAR, designed for HER3-expressing solid tumors.
HER3-targeting antibody-drug conjugate (preclinical)
A HER3-targeting antibody-drug conjugate in preclinical development that uses site-specific glycan conjugation to attach a potent cytotoxic payload with a defined DAR, designed for HER3-expressing solid tumors.
Expertise Areas
- Antibody-drug conjugate (ADC) development
- Preclinical oncology research and translational studies
- In vitro and in vivo efficacy testing (including PDX models)
- CMC aspects of ADC conjugation and characterization
Key Technologies
- Antibody-drug conjugates (ADCs)
- Site-specific glycan conjugation
- Drug-to-antibody ratio (DAR) quantification
- Monomethyl auristatin E (MMAE) payloads